540 | SAFETY OF BTK INHIBITOR‐BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA—A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META‐ANALYSIS

Documenti analoghi

• 534 | EFFICACY OF BTK INHIBITOR‐BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA—A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META‐ANALYSIS
  di: Y. Wang, et al.
  Pubblicazione: (2025)
• 536 | ORELABRUTINIB‐BASED REGIMENS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL‐WORLD STUDY
  di: Z. Wang
  Pubblicazione: (2025)
• 551 | A NETWORK META‐ANALYSIS OF EFFICACY OF ZANUBRUTINIB VERSUS FIXED‐DURATION ACALABRUTINIB PLUS VENETOCLAX IN TREATMENT‐NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA
  di: M. Shadman, et al.
  Pubblicazione: (2025)
• 546 | PATIENT REPORTED OUTCOMES AND PREDICTORS OF INHIBITOR USE IN CHRONIC LYMPHOCYTIC LEUKEMIA—AN ANALYSIS OF THE LYMPHOMA COALITION’S 2024 GLOBAL PATIENT SURVEY
  di: S. E. Kalloger, et al.
  Pubblicazione: (2025)
• 547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
  di: T. Wang, et al.
  Pubblicazione: (2025)